13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001582844
Total reported value
$143.5M
$143.5M
30 檔
63.4%
According to the latest 13F quarterly dataset, Acuta Capital Partners, LLC managed an equity portfolio of $143.5M at the end of Q4 2025, spanning 30 distinct U.S. exchange-listed positions.
Acuta Capital Partners, LLC executed strategic sector rebalancing during Q4 2025, establishing 7 new positions while fully exiting 5 holdings and trimming 6 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 17.48% | -18.59% | EXIT | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 16.62% | -0.13% | +66.90% | |
| 3 | CDTX | Cidara Therapeutics Inc | Stock-Other | 13.37% | — | -37.01% | |
| 4 | OCUL | Ocular Therapeutix Inc | Stock-Other | 8.68% | +0.07% | -9.63% | |
| 5 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 5.60% | +6.59% | — | |
| 6 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 4.48% | -1.27% | -0.47% | |
| 7 | CMPX | Compass Therapeutics Inc | Stock-Other | 3.99% | -2.28% | +30.14% | |
| 8 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 3.35% | — | +15.51% | |
| 9 | INSM | Insmed Inc | Stock-Healthcare | 3.06% | — | -32.94% | |
| 10 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.77% | +0.60% | -23.95% | |
| 11 | SRZN | Surrozen Inc | Stock-Other | 2.74% | -0.44% | — | |
| 12 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 2.73% | +0.61% | — | |
| 13 | NERV | Minerva Neurosciences Inc | Stock-Other | 1.94% | -0.30% | — | |
| 14 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.70% | +1.95% | — | |
| 15 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.70% | +1.27% | — | |
| 16 | ZYME | Zymeworks Inc | Stock-Other | 1.43% | — | — | |
| 17 | OCS | Oculis Holding AG | Stock-Other | 1.38% | -1.86% | EXIT | |
| 18 | DSGN | Design Therapeutics Inc | Stock-Other | 0.96% | +1.75% | — | |
| 19 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.88% | — | — | |
| 20 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.76% | -0.10% | — | |
| 21 | VSTM | Verastem Inc | Stock-Other | 0.75% | — | — | |
| 22 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.56% | -0.41% | EXIT | |
| 23 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.53% | +0.39% | — | |
| 24 | STRO | Sutro Biopharma Inc | Stock-Other | 0.53% | +1.48% | — | |
| 25 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.47% | — | -33.17% | |
| 26 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.45% | -1.80% | EXIT | |
| 27 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 0.45% | +0.14% | — | |
| 28 | KTTA | Pasithea Therapeutics CORP | Stock-Other | 0.39% | — | — | |
| 29 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.23% | -0.27% | EXIT | |
| 30 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | +13.9% | +66.90% | Add |
| 2 | 430 | Terns Pharmaceuticals Inc | +13.6% | +26.71% | Add |
| 3 | CMPX | Compass Therapeutics Inc | +1% | +30.14% | Add |
| 4 | SRZN | Surrozen Inc | +0.4% | — | Unchanged |
| 5 | INBX | Inhibrx Biosciences Inc | +0.3% | — | Unchanged |
| 6 | TSHA | Taysha Gene Therapies Inc | +0.2% | — | Unchanged |
| 7 | RVMD | Revolution Medicines Inc | 0% | — | Unchanged |
| 8 | ZYME | Zymeworks Inc | 0% | — | Unchanged |
| 9 | NUVB-WS | Nuvation Bio Inc -cw27 | — | — | Unchanged |
| 10 | UNCY | Unicycive Therapeutics Inc | 0% | — | Unchanged |
| 11 | LBRX | Lb Pharmaceuticals Inc | 0% | — | Unchanged |
| 12 | JAZZ | Jazz Pharmaceuticals plc | -0.1% | +15.51% | Add |
| 13 | UTHR | United Therapeutics CORP | -0.2% | — | Unchanged |
| 14 | OCS | Oculis Holding AG | -0.5% | — | Unchanged |
| 15 | DNTH | Dianthus Therapeutics Inc | -0.6% | -33.17% | Trim |
| 16 | VSTM | Verastem Inc | -0.6% | — | Unchanged |
| 17 | CDTX | Cidara Therapeutics Inc | -0.6% | -37.01% | Trim |
| 18 | DRUG | Bright Minds Biosciences Inc | -0.8% | -0.47% | Trim |
| 19 | WHWK | Whitehawk Therapeutics Inc | -1.1% | — | Unchanged |
| 20 | AMLX | Amylyx Pharmaceuticals Inc | -2% | — | Unchanged |
| 21 | ARGX | Argenx Se - Adr | -2.1% | -23.95% | Trim |
| 22 | INSM | Insmed Inc | -2.7% | -32.94% | Trim |
| 23 | OCUL | Ocular Therapeutix Inc | -5.4% | -9.63% | Trim |
| 24 | TRML | Tourmaline Bio Inc | — | EXIT | Sold out |
| 25 | NERV | Minerva Neurosciences Inc | — | NEW | New buy |
| 26 | TNGX | Tango Therapeutics Inc | — | NEW | New buy |
| 27 | ASND | Ascendis Pharma A/S | — | EXIT | Sold out |
| 28 | KRYS | Krystal Biotech Inc | — | EXIT | Sold out |
| 29 | COGT | Cogent Biosciences Inc | — | EXIT | Sold out |
| 30 | DSGN | Design Therapeutics Inc | — | NEW | New buy |
| 31 | MAZE | Maze Therapeutics Inc | — | NEW | New buy |
| 32 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 33 | STRO | Sutro Biopharma Inc | — | NEW | New buy |
| 34 | KTTA | Pasithea Therapeutics CORP | — | NEW | New buy |
| 35 | FULC | Fulcrum Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Acuta Capital Partners, LLC reported a total U.S. public equity portfolio value of $143.5M across 30 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including 430, PRAX, CDTX) accounted for 63.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
NERV
市值: $2.9M
Top Position Liquidated / Trimmed
TRML
前期市值: $12.8M
During Q4 2025, Acuta Capital Partners, LLC's top holdings by market value included 430 (17.5%)、PRAX (16.6%)、CDTX (13.4%). The largest single position, 430, represented 17.5% of total portfolio value.
In Q4 2025, Acuta Capital Partners, LLC made 22 total portfolio adjustments, initiating 7 new buys, adding to 4 positions, trimming 6 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.